Cite
HARVARD Citation
Gordon, K. et al. (2021). Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 397 (10273), pp. 475-486. [Online].